Announcements Trials
Browse Landscape

Phase

Phase 2 82Phase 3 19Phase 1/2 18Phase 1 18Phase 2/3 5Phase NA 1Phase 4 1

Status

Recruiting 5Completed 2

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 1Genitourinary 1

Conditions

Carcinoma, Hepatocellular 2Renal Pelvis and Ureter Urothelial Carcinoma 1Gallbladder Neoplasms 1Endometrial Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Cisplatin 22pembrolizumab 17Drug Therapy 16Carboplatin 15Paclitaxel 12Gemcitabine 12Dexamethasone 12Magnetic Resonance Spectroscopy 10Bevacizumab 10venetoclax 8atezolizumab 8Pemetrexed 8Oxaliplatin 8Docetaxel 8Specimen Handling 7Radiotherapy 7Nivolumab 7Cyclophosphamide 7Capecitabine 7130-nm albumin-bound paclitaxel 7Methotrexate 6durvalumab 5blinatumomab 5Cytarabine 5Androgen Antagonists 5tislelizumab 4spartalizumab 4pertuzumab 4Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × Recruiting × durvalumab × Clear all
NCT05255653 2026-05-15

RAINBO

Leiden University Medical Center

Phase 2/3 Recruiting
1,615 enrolled
Gynecologic

Endometrial Neoplasms

NCT04628767 2026-05-13

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
249 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

NCT06904170 2026-02-03

ALICE

UNICANCER

Phase 2/3 Recruiting
196 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06109272 2025-08-15

LIVIGNO-2

AbbVie

Phase 2/3 Recruiting
660 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06214572 2025-04-11

RUGB

Tata Memorial Centre

Phase 2/3 Recruiting
249 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡